PB1962: INFLUENCE OF TRANSCRIPT TYPES IN SUSTAINED DEEP MOLECULAR RESPONSE (SDMR) AND TREATMENT-FREE REMISSION (TFR) IN CHRONIC PHASE-CHRONIC MYELOID LEUKEMIA (CP-CML) PATIENTS TREATED WITH TKI

• Silvia Marce Torra,
• Aleix Méndez,
• Antonella Luciana Sturla,
• Miriam Ratia,
• Anna Angona Figueras,
• Paula Amat,
• Francisca Ferrer-Marín,
• Silvia Escribano,
• Emilia Scalzulli,
• Montserrat Cortes Sansa,
• Esther Plensa,
• Natalia Estrada,
• Marta Cabezon Marco,
• Mireia Morgades,
• Maria Alicia Senin Magan,
• Juan Carlos Hernandez-Boluda,
• Eduardo Anguita,
• Massimo Breccia,
• Valentín García-Gutiérrez,
• Blanca Xicoy Cirici,
• Lurdes Zamora

Affiliations

Silvia Marce Torra

1 ICO Badalona-Hospital Germans Trias i Pujol, Josep Carreras Leukaemia Research Instiute (IJC), Hematology Department, Badalona, Spain

Aleix Méndez

1 ICO Badalona-Hospital Germans Trias i Pujol, Josep Carreras Leukaemia Research Instiute (IJC), Hematology Department, Badalona, Spain

Antonella Luciana Sturla

2 ICO Hospitalet de Llobregat-Hospital Duran i Reynals, Hematology Department, Hospitalet de Llobregat, Spain

Miriam Ratia

2 ICO Hospitalet de Llobregat-Hospital Duran i Reynals, Hematology Department, Hospitalet de Llobregat, Spain

Anna Angona Figueras

3 ICO Girona-Hospital Josep Trueta, Hematology Department, Girona, Spain

Paula Amat

4 Hospital Clínico Universitario-INCLIVA de Valencia, Hematology Department, Valencia, Spain

Francisca Ferrer-Marín

5 Hospital General Universitario Morales Messeguer-CIBERER, UCAM, Hematology-Oncology Department, Murcia, Spain

Silvia Escribano

6 Hospital Clínico San Carlos, IML, IdISSC, Department of Medicine, Universidad Complutense de Madrid (UCM), Hematology Department, Madrid, Spain

Emilia Scalzulli

7 Policlinico Umberto 1, Sapienza University, Hematology, Department of Precision and Translational Medicine, Rome, Italy

Montserrat Cortes Sansa

8 Hospital General de Granollers, Hematology Department, Granollers, Spain

Esther Plensa

9 Consorci Sanitaria del Maresme, Hospital de Mataró, Hematology Department, Mataró, Spain

Natalia Estrada

1 ICO Badalona-Hospital Germans Trias i Pujol, Josep Carreras Leukaemia Research Instiute (IJC), Hematology Department, Badalona, Spain

Marta Cabezon Marco

1 ICO Badalona-Hospital Germans Trias i Pujol, Josep Carreras Leukaemia Research Instiute (IJC), Hematology Department, Badalona, Spain

Mireia Morgades

1 ICO Badalona-Hospital Germans Trias i Pujol, Josep Carreras Leukaemia Research Instiute (IJC), Hematology Department, Badalona, Spain

Maria Alicia Senin Magan

2 ICO Hospitalet de Llobregat-Hospital Duran i Reynals, Hematology Department, Hospitalet de Llobregat, Spain

Juan Carlos Hernandez-Boluda

4 Hospital Clínico Universitario-INCLIVA de Valencia, Hematology Department, Valencia, Spain

Eduardo Anguita

6 Hospital Clínico San Carlos, IML, IdISSC, Department of Medicine, Universidad Complutense de Madrid (UCM), Hematology Department, Madrid, Spain

Massimo Breccia

7 Policlinico Umberto 1, Sapienza University, Hematology, Department of Precision and Translational Medicine, Rome, Italy

Valentín García-Gutiérrez

10 Hospital Ramón y Cajal, Hematology Department, Madrid, Spain

Blanca Xicoy Cirici

1 ICO Badalona-Hospital Germans Trias i Pujol, Josep Carreras Leukaemia Research Instiute (IJC), Hematology Department, Badalona, Spain

Lurdes Zamora

1 ICO Badalona-Hospital Germans Trias i Pujol, Josep Carreras Leukaemia Research Instiute (IJC), Hematology Department, Badalona, Spain